Prognostic value of systemic immune-inflammation index (SII) as a novel
marker in patients with atrial fibrillation
Abstract
Background Recently, inflammation plays an essential role in the
prognosis of atrial fibrillation (AF) patients. Systemic
immune-inflammation index (SII), reflecting the inflammation status,
which is measured by the formula: neutrophil count × platelet
count/lymphocyte count, is a powerful prognostic marker in several types
of cancer and cardiovascular disease. However, no information regarding
the prognostic value of SII in patients with AF is available. Methods
and results We retrospectively enrolled 1768 AF patients in our study.
Demographic characteristics, laboratory data and echocardiography were
measured and collected on admission. The primary endpoints were death
from all causes and death from cardiovascular diseases. The secondary
endpoints were major bleeding and stroke. During a mean follow-up of
22.35 months, 155 patients occurred death from all causes. For further
analysis, patients were categorized into two groups according to the
optimal cutoff value of SII level determined by using receiver operating
characteristics curve analysis. The incidence of death from all causes
and death from cardiovascular diseases in high SII group is
significantly higher compared with that in low SII group. However, no
significant differences were detected between two groups for the
secondary endpoints (p>0.05). On multivariable Cox analysis
with adjustment of potential confounders, the risk of death from all
causes and death from cardiovascular diseases increased by 77.6% and
51.2%, respectively, in high SII group. Conclusion Systemic
immune-inflammation index was significantly associated poor outcomes and
was an independent predictor for mortality in atrial fibrillation
patients.